Nomura Maintains Neutral Rating on Torrent Pharma, Sets Rs 4,670 Target
Nomura expects strong Q2 FY27 results, market-beating growth in India, export tailwinds from rupee depreciation and early synergies from the JB Pharma acquisition.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.